Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer. McCauley spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge, contends Kevin Foust, PhD, senior vice president for preclinical and translational medicine at Jaguar Gene Therapy. Foust spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors, said Sangamo CEO Sandy Macrae, PhD, at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
11.7T MR spectroscopy quantifies brain glucose metabolism
French researchers have developed a new MR (magnetic resonance) spectroscopy approach to study brain glucose metabolism, a process significantly involved in Alzheimer's disease. They presented their work in an animal study at the annual meeting of the International Society for Magnetic Resonance in Medicine. Read More
Sample management, characterization is a growing challenge in CGT
From academic research centers to small biotechs to large pharmaceutical companies, the numbers of biosamples and measurements are growing exponentially in the field of cell and gene therapy (CGT). Andrea O'Hara and David Lewandowski of Azenta Life Sciences, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting about the challenge of sample management and characterization. Read More
Autologous cell therapy has its limitations, risks
Cell-based therapies generated using a patient's own cells, called autologous cell therapy, have their own inherent risks and limitations, contends Roman Vincent, senior global director of strategic marketing at MaxCyte. Vincent spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
What's needed for cell and gene therapies to become the new standard of care?
Cell and gene therapies (CGTs) have the potential to be the new standard of care. Delara Motlagh, PhD, general manager at Terumo Blood and Cell Technologies, told ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting that increasing access to CGTs is critical to making that a reality. Read More
Automation, standardization hold potential for overcoming CGT manufacturing challenges
Challenges in cell and gene therapy (CGT) manufacturing can be overcome by fully automating and standardizing the process, contends David Smith, vice president of technical operations at Ori Biotech. Smith spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting about Ori Biotech's new digital platform that closes, automates, and standardizes CGT manufacturing. Read More
CGT ecosystem is only way to accelerate development for more patients: Autolomous COO
Digital solutions provider Autolomous specializes in building solutions for the cell and gene therapy (CGT) industry with an emphasis on collaborative partnerships with suppliers across the value chain. Kwok Pang, the company’s chief operating officer (COO), spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
Galipeau to replace Levine as ISCT president
Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, as the next president (2022-2024) of the International Society for Cell & Gene Therapy (ISCT). Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter